CancerVax completes enrollment in melanoma Phase III

CNVX completed enrollment of 1,118 stage III melanoma patients in a Phase III trial of its Canvaxin immunotherapy. The compound also is in an ongoing Phase III trial in patients with stage IV melanoma...